Abstract Genital infection by human papillomavirus (HPV) tends to occur more frequently in patients with conditions associated with immune suppression. Systemic lupus erythematosus (SLE) is an immunological disorder characterized by generalized inXammation and a number of clinical manifestations and circulating autoantibodies. The aim of the present study was to determine the prevalence of genital HPV infection among female SLE patients. Women diagnosed with SLE based on American College of Rheumatology classiWcation criteria followed at rheumatology outpatient clinic of the Escola Bahiana de Medicina e Saude Publica, Salvador, Brazil, were included in the study. As a comparison group, clinically healthy women who were attending the gynecology outpatient clinic for routine examination at the same institution were recruited. Testing for cervical HPV infection was performed using the nested polymerase chain reaction technique. Eighty-eight female SLE patients (mean age, 41.4 § 11.6 years) and seventy healthy female subjects (control group) were studied. The prevalence of HPV infection was 80.7 % (71/88) in the SLE group and 35.7 % (25/70) in the control group (p < 0.0001). After adjustment of the variables (early sexual activity, number of partners and obstetric history), the odds ratio (OR) for genital HPV infection in women with SLE was 7.2 (95 % CI, 2.9 to 17.8; p = 0.0001). The use of immunosuppressive drugs was not associated with a higher prevalence of HPV infection. This study demonstrated that SLE patients have a higher prevalence of genital HPV infection, even when exposed to less potential risk factors for the virus.
Introduction
The human papillomavirus (HPV) is composed of a group of DNA viruses of the family papoviridae. More than 200 types of HPV can infect humans, and the anogenital region is the most commonly aVected [1] . This type of virus can be divided into two groups: low-oncogenic HPV, which is represented primarily by types 06 and 11, and high-oncogenic HPV, which commonly refer to types 16 and 18. Case-control studies conWrm that the HPV DNA can be detected in 99.7 % of women with histologically conWrmed cervical cancer, as opposed to 13.4 % of controls [2] . The presence of HPV is a necessary element, but not the only component required for the development of cervical cancer.
The potential risk factors for cervical HPV infection are the following: age between 20 and 24, early sexual activity, multiple sexual partners, tobacco use, pregnancy, poor nutritional state, history of sexual transmitted diseases (STDs) such as genital herpes and Chlamydia trachomatis [3] . Immunosuppression is also an important risk factor [4] [5] [6] .
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease of unknown origin, characterized by chronic inXammation and diverse clinical manifestations as well as by the presence of diVerent autoantibodies. Although SLE can occur at any age, it is more frequent among people between the ages of 20 and 45 with the highest incidence occurring in individuals around the age of 30 and aVects 10-12 times as many women as men. Individuals with SLE are generally immunosuppressed by the disease itself or by the use of medications which inhibit the immune system [6] . The normal defense mechanisms against oncogenic viruses are therefore compromised in these patients, and theoretically, there is an increased risk of cervical abnormalities in them. The objective of this study was to determine the prevalence of cervical HPV infection and evaluate the presence of cervical lesions in women with SLE, in comparison with a group of clinically healthy women.
Materials and methods
This study is a cross-sectional analysis of the prevalence of cervical HPV infection in women with SLE. A group of women diagnosed with SLE and a control group of clinically healthy women followed in rheumatology and gynecology clinics, respectively, at the Escola Bahiana de Medicina e Saúde Pública were included in the study. The diagnosis of SLE was based upon the American College of Rheumatology classiWcation criteria [7] . Inclusion criteria for the study were over 18 years of age and sexually active. Exclusion criteria were psychiatric disorders, having undergone total hysterectomy, and pregnancy. This study was approved by the research Ethics Committee of our Institution. All patients freely signed informed consent forms before agreeing to take part in the study.
The patients responded to a structured questionnaire that evaluated sociodemographic, behavioral, rheumatological and gynecological/obstetric aspects of their lives. After the interview, physical and gynecological examinations were carried out. Specimens for Papanicolaou smears were collected from ectocervix and endocervix using an Ayres spatula and cytobrush, respectively. Squamous cell abnormalities seen in the Papanicolaou smears were classiWed as low-grade or high-grade squamous intraepithelial lesions, in accordance with the 2001 Bethesda System [8] . Colposcopic examinations were carried out in all of the women by the gynecologist. If a lesion was indicated by the colposcopy or cytology results, it was further evaluated by means of biopsies, which were examined and classiWed in accordance with the CIN system [9] . Cytological samples were collected from the ecto-and endocervices for HPV testing, using sterile swabs. The cervical sample was transported in 400 l of TE [10 mM Tris-HCl pH 8.0 and 1 mM ethylenediaminetetraacetic acid (EDTA)] and stored at ¡20°C. DNA extraction was performed using the commercial QIAamp ® DNA Mini Kit (QIAGEN, Germany), according to the manufacturer's protocol. The samples were frozen at ¡20°C until used. These samples were analyzed using the polymerase chain reaction (PCR) technique in the Advanced Laboratory of Public Health (LASP) of FIOCRUZ in Salvador, Brazil. For DNA ampliWcation, it was used the nested PCR (n-PCR) method, as suggested by Demathe et al. [10] with some modiWcation. For the Wrst round, it was used the MY09/11 consensus outer primer pair, capable of amplifying a 450 base pair fragment directed to a highly conserved region of the viral protein L1. In the second round, it was used the GP5+/GP6+ consensus inner primer pairs to amplify a 150 base pair fragment, restrained in the 450 base pair fragment ampliWed previously. The ampliWcation reaction used a standard system for each round of the reaction containing a Wnal volume of 12.5 l. The Wrst round was composed of 1.25 l of the PCR buVer (10£), 0.4 l of MgCl2 (50 mM), 2 l of dNTP (1.25 mM), 0.3 l of Taq DNA polymerase (5U/ l), 1 l of each outer primer (10 pmol/ l), 5.5 l of water and 1 l of DNA template (50-100 ng/ l). The ampliWcation was performed using an Applied Biosystems Veritas™ Thermal Cycler with the following cycling temperatures: initial heating at 94°C for 1 min, 40 cycles of denaturation at 95°C for 1 min, annealing at 55°C for 1 min and extension at 72°C for 1 min, followed by a Wnal extension at 72°C for 5 min. The second round was performed using Top Taq Master Mix Kit (QIAGEN, Germany), consisting of 6.5 l of TopTaq Master Mix (2£), 1.3 l of each inner primer (50 pmol/ l), 1.3 l of Coral Load Concentrate (10£), 1.1 l of water and 1 l of the Wrst round PCR product. The ampliWcation was performed with the following cycling temperatures: initial heating at 94°C for 4 min, 35 cycles of denaturation at 94°C for 1 min, annealing at 40°C for 2 min and extension at 72°C for 1 and a half minutes, followed by Wnal extension for 72°C for 4 min. To avoid false-negative results, an additional PCR was performed using a primers pair capable of amplifying a region of 268 base pairs of human -globin protein. The PCR product was detected using agarose gel electrophoresis (2 %) and stained with ethidium bromide. The positive and negative controls were samples analyzed using the cobas ® 4800 HPV Test, provided by the DNA Laboratory, Salvador-Bahia. Internal negative control, prepared with the same reagents, replacing the DNA template by water was also used.
The 95 % conWdence interval (CI) was established to estimate the prevalence of HPV in this population, and p value · 0.05 was considered statistically signiWcant. The categorical variables are expressed in absolute values and percentages, and the quantities are described in mean and standard deviation. Pearson's chi-squared test and Fischer's exact test were used to compare the categorical variables between the two groups. Student's t test was used to compare continuous variables between the two groups, taking into consideration the parametric distribution of the studied samples, conWrmed by the histogram and by congruence between the mean and median. The association between SLE and HPV infection was investigated taking into account known potential risk factors for genital infection by this virus. The odds ratio (OR) was determined adjusting the variables that were at least moderately associated with HPV infection. Statistical analysis was carried out using SPSS software (Statistical Package for the Social Sciences), version 17.0.
Results
The SLE group was composed of 88 patients with a mean age of 41.4 § 11.6 years, older than the control group of 70 clinically healthy women (29.0 § 5.9 years) (p < 0.0001). The mean age at Wrst sexual intercourse was at 19.9 § 4.9 years among SLE patients and 17.6 § 4.1 years in the control group (p = 0.002). The number of sexual partners was slightly lower in women with SLE (2.8 § 2.2) than in the control group (3.79 § 4.5); however, this diVerence was not statistically signiWcant. The prevalence of HPV cervical infection was 80.7 % (71/88) in the SLE group and 35.7 % in the control group (p < 0.0001) ( Table 1 ). The OR for HPV infection in women with SLE was 7.1 (95 % CI; 2.9-17.7; p = 0.0001) after the following variables were adjusted: age, start of sexual activity, number of sexual partners, condom use and obstetric history ( Table 2) .
There was no statistically signiWcant diVerence between the two groups with regard to cytological abnormalities:
LGSIL, HGSIL and ASC-US. However, normal cytopathological results were less commonly observed in the SLE group (1/71 or 1.4 %) than in the control group (5/25 or 20 %); p < 0.0004 (Table 3) . Regarding risk factors associated with cervical HPV infection in the group of SLE patients, condom use was less prevalent in the group of patients with cervical HPV infection (9.9 %) than in the group of patients who tested negative for HPV (29.4 %); p = 0.03. There was no statistically signiWcant diVerence with relation to the age at Wrst sexual intercourse, number of sexual partners, time of the diagnosis of SLE or the use of immunosuppressive drugs (deWned as the use during any period of the illness of any of the following immunosuppressive drugs: azathioprine, methotrexate, cyclophosphamide, cyclosporine, mycophenolate mofetil, or mycophenolate sodium) (Table 4) . However, abnormal colposcopic Wndings were more frequent in women with SLE who were infected by HPV and used immunosuppressive drugs (12 or 24.5 %) than they were in the group that did not use immunosuppressive drugs (1 or 4.5 %) p = 0.05 (Table 5) .
Discussion
Data in the literature consistently demonstrate that women with SLE are at increased risk of the development of cervical cytological abnormalities [11] [12] [13] . However, few studies conWrm the molecular diagnosis of cervical HPV infection [11, 14] . HPV infection can precede the development of cytological abnormalities by years, making the persistence of the virus in the tissue an important risk factor for the progression of cellular changes. This study demonstrated a higher prevalence of cervical HPV infection in women with SLE when compared with clinically healthy women, despite less exposure to potential risk factors for HPV among the group of women with SLE (older age, greater age at Wrst sexual intercourse, and smaller number of sexual partners than the control group). In a multivariate logistic regression model, the presence of SLE was an independent predictor for HPV infection. The prevalence of cervical HPV infection found in women with SLE was greater than what has been described in the literature. Tam [14] . This diVerence can be attributed to diagnostic techniques used. In the cited studies, HPV infection was demonstrated by simple PCR, using only one consensus primer pair. In this study, the n-PCR technique was used, which combines two diVerent pairs of consensus primers. The advantage of this last technique is the substantial increase in sensitivity [10, 15] . However, we cannot exclude the possible contribution of still undeWned genetic factors in the diVerent populations studied.
Women with SLE are more prone to infection by diVerent etiologic agents than are the clinically healthy population [16] . This greater susceptibility can be explained by the diVerent intrinsic abnormalities of the disease, associated with the use of immunosuppressive therapy [17] . Patients with SLE have defective mechanisms that are involved with the innate immune response, such as inappropriate activation of Toll-like receptors for self-antigens, decreased clearance of apoptotic bodies, deWciency of mannose-binding lectin and complement deWciency. Further, SLE patients have many abnormalities in their adaptive immune responses, with a loss of self-tolerance in T and B lymphocytes and the production of various antibodies against self-antigens, as well as the lower production of certain cytokines. These immunological abnormalities are associated with an elevated risk of bacterial infections. Similarly, diVerent types of viral infections seem to be more common in these patients [18] ; this is the case with Parvovirus B19 infection [19, 20] , cytomegalovirus [21] , varicella-zoster virus [22] , Epstein--Barr virus [23] and herpes simplex virus [24] . These immune disorders also seem to be associated with an increased risk of cervical HPV infection, with more tissue persistence and the development of malignant lesions. It is thus assumed that cervical HPV infection in these patients tends to spontaneously resolve itself less frequently than it does in healthy women. Regarding immunosuppressive drugs, there is still no consensus in the literature as to whether or not the use of these drugs is associated with a higher prevalence of cervical HPV infection in women with SLE. Some studies associate the use of azathioprine [25] and cyclophosphamide [6, 26] with a higher prevalence of cervical HPV infection in women with SLE. The same phenomenon was observed in patients without lupus who used azathioprine after renal transplantation [27] . However, this association was not observed by other authors [11, 12] . In this study the use of immunosuppressive drugs was not associated with a greater prevalence of cervical HPV infection in women with SLE. Nevertheless, this Wnding should be interpreted cautiously as the number of SLE patients who did not use immunosuppressive drugs was relatively low. Curiously, in SLE patients infected by HPV, it was observed that those who used immunosuppressive drugs had a higher incidence of abnormal colposcopic Wndings than those who did not use the drugs. However, the cross-sectional nature of the study did not allow for the patients to be monitored and the eventual evolution to cervical cancer.
In conclusion, the results of this study indicate that women with SLE have a higher incidence of cervical HPV infection than the control group. This high prevalence was found despite the fact that the women with SLE had been exposed to fewer potential risk factors for HPV. Therefore, we recommend that patients with lupus have regular gynecological evaluations, with shorter intervals in between examinations than the general population. Additionally, although not evaluated in the present study, perhaps the use of prophylactic HPV vaccines could be a valuable tool for these patients. However, studies are necessary to Wnd out whether the eYcacy of these vaccines could be modiWed due to immunosuppression imposed by the disease and/or by the drugs used for its treatment.
